BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis
Ann Rheum Dis 2025;0:1−9
Hu et al. report that anti-BCMA only CAR T cell can help LN patients safely and effectively, indicating its potential to be a feasible therapeutic strategy in treating autoimmune diseases with abnormal humoral immune responses.
Hu et al. initiated a single-arm study that evaluated the safety profiles and therapeutic efficacy of a novel BCMA-only targeting CAR T cell product in treating refractory LN. Authors demonstrated that anti-BCMA CAR T cell therapy depleted B cells in patients with LN, promote immune reconstitution and induce drug-free remission safely and effectively indicating the feasibility of BCMA-only-targeting strategies for treating autoimmune diseases with abnormal humoral immune responses using CAR products.